Pharma

Bayer Announces Positive Phase III Results for Non-Hormonal Treatment in Menopause-Related Vasomotor Symptoms

Eli Lilly’s LillyDirect: Implications for Direct-to-Consumer Women’s Health Startups

Cosette Acquires HSDD Treatment Vyleesi from Palatin for $12M Amid Market Challenges

Organon Expands European Portfolio with Lilly Migraine Medicines

Astellas’ VEOZAH Wins EC Approval to Treat Menopause-Related Hot Flashes

Ferring Survey Reveals Knowledge Gap and Emotional Toll of Infertility amidst Record-low Birth Rates in Asia

Recent Study Reveals Lasting Benefits of Eli Lily’s Verzenio in Early Stage Breast Cancer Treatment

Health Canada Approves MYFEMBREE for the Treatment of Endometriosis and Uterine Fibroids

ASRM Announces $5 Million Endowment from Ferring Pharmaceuticals

Besins Healthcare Opens New State-of-the-Art Hormone Factory in Response to Surge in Demand for HRT and Fertility Support

Asieris’ Cevira, the First Non-Vaccine Investigational Product for Cervical HSIL, Has Achieved Its Primary Endpoint

Gedeon Richter and Sumitomo Pharma Receive CHMP Approval for Endometriosis Treatment RYEQO

Palatin Technologies Partners with UpScriptHealth to Ease Access to HSDD Treatment Vyleesi

Perrigo Receives FDA Approval for Opill Over-the-Counter Oral Contraceptive

Pharma Company Fresenius Kabi Launches Generic Fertility Treatment

FDA Approves Medicines360’s LILETTA for the Treatment of Heavy Menstrual Bleeding

Freya Biosciences’ FB101 Shows Promise in Treating Vaginal Dysbiosis

Janssen’s Nipocalimab Shows Promise for Treatment of High-Risk Pregnancies with Severe HDFN in Phase 2 Trial

Vistagen’s PH80 Nasal Spray Shows Promising Results in Menopausal Hot Flash Study

Futura Medical Raises £4.37M After Winning FDA Approval for Its ED Topical Gel

Women’s Health Company Mithra Reports Promising Data for Its CSF-1R Inhibitor in Preclinical Cancer Models

Roche’s HPV Screening Test Receives WHO Prequalification

Shine a Light on HS: Novartis Launches Awareness Campaign for Chronic Rare Skin Disease

Novartis’ Kisqali Shows Promising Results in Reducing Breast Cancer Recurrence